WallStSmart

Silicon Laboratories Inc (SLAB)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Silicon Laboratories Inc generates 203% more annual revenue ($784.76M vs $258.90M). SLAB leads profitability with a -8.3% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

SLAB

Avoid

28

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 4.0Quality: 7.8
Piotroski: 4/9Altman Z: 5.76

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for SLAB.

ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SLAB2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
5.7610/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
25.2%8/10

Revenue surging 25.2% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

SLAB4 concerns · Avg: 2.0/10
PEG RatioValuation
3.122/10

Expensive relative to growth rate

Return on EquityProfitability
-6.0%2/10

ROE of -6.0% — below average capital efficiency

EPS GrowthGrowth
-46.7%2/10

Earnings declined 46.7%

Free Cash FlowQuality
$-1.63M2/10

Negative free cash flow — burning cash

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : SLAB

The strongest argument for SLAB centers on Altman Z-Score, Revenue Growth. Revenue growth of 25.2% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : SLAB

The primary concerns for SLAB are PEG Ratio, Return on Equity, EPS Growth.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

SLAB profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SEMICONDUCTORS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 28/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Silicon Laboratories Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Silicon Laboratories Inc., a factory-less semiconductor company, provides mixed-signal integrated circuits (ICs) in the United States, China, and internationally. The company is headquartered in Austin, Texas.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?